Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Zymeworks BC Inc (NASDAQ: ZYME) closed at $23.17 up 0.30% from its previous closing price of $23.1. In other words, the price has increased by $0.30 from its previous closing price. On the day, 0.98 million shares were traded. ZYME stock price reached its highest trading level at $23.81 during the session, while it also had its lowest trading level at $22.81.
Ratios:
For a deeper understanding of Zymeworks BC Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 6.94. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On December 03, 2025, Citizens JMP started tracking the stock assigning a Mkt Outperform rating and target price of $32.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 05 ’26 when Smith Jeffrey T L sold 10,538 shares for $25.10 per share. The transaction valued at 264,471 led to the insider holds 18,352 shares of the business.
Galbraith Kenneth sold 54,343 shares of ZYME for $1,363,841 on Jan 05 ’26. The Chair & CEO now owns 158,286 shares after completing the transaction at $25.10 per share. On Jan 05 ’26, another insider, Moore Paul Andrew, who serves as the Chief Scientific Officer of the company, sold 20,110 shares for $25.10 each. As a result, the insider received 504,699 and left with 31,212 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 1754788864 and an Enterprise Value of 1500933504. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.76. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.95 while its Price-to-Book (P/B) ratio in mrq is 5.48. Its current Enterprise Value per Revenue stands at 11.161 whereas that against EBITDA is -24.616.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.25, which has changed by 0.6597421 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $28.49, while it has fallen to a 52-week low of $9.03. The 50-Day Moving Average of the stock is -2.56%, while the 200-Day Moving Average is calculated to be 42.71%.
Shares Statistics:
For the past three months, ZYME has traded an average of 1.19M shares per day and 1065070 over the past ten days. A total of 75.14M shares are outstanding, with a floating share count of 72.77M. Insiders hold about 3.38% of the company’s shares, while institutions hold 98.67% stake in the company. Shares short for ZYME as of 1765756800 were 3938970 with a Short Ratio of 3.30, compared to 1763078400 on 8541535. Therefore, it implies a Short% of Shares Outstanding of 3938970 and a Short% of Float of 7.71.
Earnings Estimates
Zymeworks BC Inc (ZYME) is currently under the scrutiny of 10.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.09, with high estimates of $0.55 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$0.13 and -$1.25 for the fiscal current year, implying an average EPS of -$0.87. EPS for the following year is $0.27, with 11.0 analysts recommending between $3.77 and -$1.52.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $19.49M this quarter.It ranges from a high estimate of $59M to a low estimate of $1.2M. As of. The current estimate, Zymeworks BC Inc’s year-ago sales were $31.03MFor the next quarter, 10 analysts are estimating revenue of $24.2M. There is a high estimate of $29.8M for the next quarter, whereas the lowest estimate is $14.58M.
A total of 12 analysts have provided revenue estimates for ZYME’s current fiscal year. The highest revenue estimate was $162.09M, while the lowest revenue estimate was $104.5M, resulting in an average revenue estimate of $122.89M. In the same quarter a year ago, actual revenue was $76.3MBased on 12 analysts’ estimates, the company’s revenue will be $254.4M in the next fiscal year. The high estimate is $502.5M and the low estimate is $96.08M.
